16 studies on Growth hormone secretagogue mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**The sustained reduction in the LDL-C/HDL-C ratio** is clinically meaningful because this ratio is an independent predictor of cardiovascular events, and oral GH secretagogues are already being explored for body comp…
**The existence of a deeply conserved GHS-R strongly supports the eventual identification of an endogenous ghrelin-axis ligand**, providing a rational pharmacological target for reversing age-related GH decline. For c…
**Adenosine — an endogenous purine nucleoside — is now a demonstrated `GHS-R` agonist**, fundamentally reshaping the view of what constitutes a natural GHS-R ligand and suggesting that purinergic signalling intersects…
**Hexarelin and MK-0677 do not bind to the same receptor populations in peripheral tissues** — a distinction with direct implications for anyone selecting between peptidyl and non-peptidyl GHS compounds. For cardiovas…
**The octanoyl fatty-acid modification on ghrelin is non-negotiable for receptor engagement**, directly validating why unacylated ghrelin fragments lack GH-releasing potency. For clinicians and researchers, this confi…
**The identification of `GPR38` as a GHS-R family member with motilin as its ligand** reveals that GH secretagogue pharmacology is entangled with gut-motility signaling — a consideration for clinicians and researchers…
**Oral bioavailability combined with significant anabolic output** positions SM-130686 in the same practical niche as MK-677 but with a structurally novel scaffold — potentially relevant for researchers seeking altern…
**Oral MK-677 at 25 mg/day demonstrably attenuates age-related lean mass loss** and restores `IGF-1` to youthful concentrations, establishing proof-of-concept that `GHSR` agonism can counter one measurable dimension o…
**The ago-allosteric model for MK-677 and GHRP-6 is not supported in this assay system** — meaning assumptions about synergistic or supra-additive effects when combining ghrelin-pathway compounds with these secretagog…
For clinicians and individuals exploring anabolic or anti-aging protocols, this review highlights GHSs as a potentially safer alternative to direct GH administration by preserving physiological feedback loops. The pri…
**Glucocorticoid users do not need to forgo ipamorelin co-administration out of concern that the steroid will block GH release** — this study directly demonstrates the GH axis remains responsive. For clinicians managi…
**Chronic ipamorelin pretreatment uniquely sensitises the pituitary somatotroph population** to respond to subsequent GHS or GHRH stimulation — a 'priming' phenomenon that does not occur after equivalent chronic GHRH …
**Both ghrelin and its receptor are now fully characterised in a single teleost species**, enabling controlled mechanistic studies of the ghrelin/GHSR axis without cross-species extrapolation. The finding that **ipamo…
**Sustained, multi-dose ipamorelin infusion is required to fully restore gut function after surgery** — a single bolus only partially addresses POI by accelerating initial transit without correcting the broader recove…
These findings directly inform and improve anti-doping testing protocols. By identifying specific, long-lasting metabolites for each GHRP, labs can create more robust screening methods that significantly extend the de…